1. At the end of 2 years in the landmark CATT for nAMD, which treatment group had the least gain in vision, greatest lesion growth, and greatest likelihood of having macular fluid?

2. The TAE approach to treating nAMD with anti-VEGF therapy provides all the following, EXCEPT:

3. Which clinical/diagnostic test is the primary tool for guiding decisions on the appropriate anti-VEGF treatment interval in a TAE management approach for a patient with nAMD?

« Return to Activity